Xenocor, a Salt Lake City, UT-based medical device company, raised $10M in Series A funding.
The round was led by GenHenn Venture Fund I with participation from Baranco Investments, Barvest Ventures, and Patel Family Investments. Michael J. Hennessy Jr., GenHenn Capital will join the Xenocor board of directors. In conjunction with the funding, Michael J. Hennessy Jr., GenHenn Capital, will join the Xenocor board of directors.
Led by Charles DeCoster IV, CEO, Xenocor designs, develops and markets medical devices, including the Saberscope system, which is FDA cleared and intended for use in diagnostic and therapeutic procedures for endoscopy and endoscopic surgery within the thoracic and peritoneal cavities, including the female reproductive system organs.
The company intends to use the funds for the 2023 launch of the Saberscope and to continue executing on its innovation roadmap.
FinSMEs
18/04/2023